Χώρα: Σιγκαπούρη
Γλώσσα: Αγγλικά
Πηγή: HSA (Health Sciences Authority)
Mirabegron
ASTELLAS PHARMA SINGAPORE PTE. LTD.
G04BD12
25 mg
TABLET, FILM COATED, EXTENDED RELEASE
Mirabegron 25 mg
ORAL
Prescription Only
Avara Pharmaceutical Technologies. Inc.
ACTIVE
2014-09-15
1.4.3 Package Insert for Singapore 1 _ _ 1. NAME OF THE MEDICINAL PRODUCT Betmiga ® prolonged-release tablets 25 mg Betmiga ® prolonged-release tablets 50 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg of mirabegron. Each tablet contains 50 mg of mirabegron. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. 25mg: Oval, brown tablet, debossed with the company logo and “325” on the same side. 50mg: Oval, yellow tablet, debossed with the company logo and “355” on the same side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome._ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults (including elderly patients)_ The recommended starting dose of Betmiga is 25 mg once daily. Based on individual patient efficacy and tolerability the dose may be increased to 50mg once daily. Betmiga can be taken with or without food. _Special populations _ _ _ _Renal and hepatic impairment _ _ _ No dose adjustment is necessary in patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m 2 as estimated by MDRD).In patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ), the recommended dose is 25 mg dose once daily with or without food. Betmiga has not been studied in patients with End Stage Renal Disease (eGFR < 15 mL/min/1.73 m 2 or patients requiring haemodialysis) (see sections 4.4 and 5.2). No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Cla Διαβάστε το πλήρες έγγραφο
1 1.4.3 Package Insert for Singapore 2 _ _ 1. NAME OF THE MEDICINAL PRODUCT Betmiga ® prolonged-release tablets 25 mg Betmiga ® prolonged-release tablets 50 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 25 mg of mirabegron. Each tablet contains 50 mg of mirabegron. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Prolonged-release tablet. 25mg: Oval, brown tablet, debossed with the company logo and “325” on the same side. 50mg: Oval, yellow tablet, debossed with the company logo and “355” on the same side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adult patients with overactive bladder (OAB) syndrome. _ _ 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults (including elderly patients)_ The recommended starting dose of Betmiga is 25 mg once daily. Based on individual patient efficacy and tolerability the dose may be increased to 50mg once daily. Betmiga can be taken with or without food. _Special populations _ _ _ _Renal and hepatic impairment _ No dose adjustment is necessary in patients with mild to moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m 2 as estimated by MDRD).In patients with severe renal impairment (eGFR 15 to 29 mL/min/1.73 m 2 ), the recommended dose is 25 mg dose once daily with or without food. Betmiga has not been studied in patients with End Stage Renal Disease (eGFR < 15 mL/min/1.73 m 2 or patients requiring haemodialysis) (see sections 4.4 and 5.2). No dose adjustment is necessary in patients with mild hepatic impairment (Child-Pugh Class A). In patients with moderate hepatic impairment (Child-Pugh Class B) the recommended dose is 25 mg once daily with or without food. Betmiga has not be studied in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.4 and 5.2). _Gender _ No dose adjustment is necessary according to gender. 3 _Paediatric population _ The safety and efficacy of mirab Διαβάστε το πλήρες έγγραφο